We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » After a Rocky Debut, Esai’s Lecanemab Advances as Another Alzheimer’s Contender
After a Rocky Debut, Esai’s Lecanemab Advances as Another Alzheimer’s Contender
Buoyed by the FDA’s recent approval of Biogen’s Alzheimer’s disease (AD) treatment Aduhelm, Esai is hoping to seek an accelerated approval for its antiamyloid candidate lecanemab.